Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors.
Hampel
G
G
Department of Urology, Charité der Humboldt Universität, Berlin, Germany.
Hosseini
R
R
Jung
K
K
D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D005920:Glomerular Mesangium / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000201:enzymology / Q000378:metabolism*; D007700:Kinetics; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D016559:Tacrolimus / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D019715:Tissue Inhibitor of Metalloproteinase-1; D014409:Tumor Necrosis Factor-alpha; D019716:Tissue Inhibitor of Metalloproteinase-2; D016572:Cyclosporine; D020778:Matrix Metalloproteinase 2; D020781:Matrix Metalloproteinase 1; D013755:Tetradecanoylphorbol Acetate; D016559:Tacrolimus